Compare Realty Income Corp (O) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs BIO-TECHNE Corp — how do they compare? Realty Income Corp trades at $60.34 (market cap $57.74B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Realty Income Corp is far larger — about 5.1× BIO-TECHNE Corp's market cap, and Realty Income Corp pays the higher dividend (5.33%). Which is the better fit depends on your goals.
| O | TECH | |
|---|---|---|
Market Cap | $57.74B | $11.34B |
Sector | Real Estate | Health |
52-Week High | $67.56 | $72.48 |
52-Week Low | $55.93 | $43.31 |
Enterprise Value | $88.37B | $11.36B |
Dividend Yield | 5.33% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $61.02, down 0.38% on the day, with a bearish technical signal from moving averages. The stock has missed earnings expectations for the last three quarters, but revenue grew to $5.75B in 2025 with a net income margin of 21.23%. Recent news highlights the company's 136th consecutive monthly dividend increase to $0.2715 per share, underscoring its income-focused appeal amid a 5.3% yield.
The outlook is mixed: analyst consensus leans hold with a $66.50 price target, suggesting modest upside, but rising debt levels and interest rate sensitivity pose risks. Earnings misses and a high P/E of 44.54 indicate valuation concerns, though dividend growth and high occupancy support income stability for long-term investors.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
